Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1. Beerse, Belgium (28 February 2025) - Johnson & Johnson today announced that the Com ...
For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback